News headlines about Zimmer Biomet (NYSE:ZBH) have been trending somewhat positive on Saturday, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zimmer Biomet earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 45.8875424024045 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern’s rankings:
- Royal Bank of Canada Increases Zimmer Biomet (ZBH) Price Target to $140.00 (americanbankingnews.com)
- Zimmer Biomet (ZBH) Earns Buy Rating from BMO Capital Markets (americanbankingnews.com)
- Zimmer Biomet (ZBH) Upgraded to “Buy” by Guggenheim (americanbankingnews.com)
- Oregon Surgical Institute to Implement Zimmer Biomet Signature Solutions Outpatient Program (finance.yahoo.com)
- Consort Medical (CSRMY) vs. Zimmer Biomet (ZBH) Head-To-Head Comparison (americanbankingnews.com)
Several brokerages have weighed in on ZBH. BMO Capital Markets reaffirmed a “buy” rating and set a $144.00 target price on shares of Zimmer Biomet in a research note on Tuesday, January 30th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $140.00 target price on shares of Zimmer Biomet in a research note on Tuesday, January 30th. SunTrust Banks increased their target price on shares of Zimmer Biomet to $142.00 and gave the stock a “buy” rating in a research note on Monday, January 29th. Morgan Stanley increased their target price on shares of Zimmer Biomet from $140.00 to $150.00 in a research note on Monday, January 29th. Finally, Needham & Company LLC increased their target price on shares of Zimmer Biomet from $144.00 to $155.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, January 30th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $138.80.
Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $2.10. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The business had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.03 billion. During the same quarter last year, the firm posted $2.14 earnings per share. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. equities analysts predict that Zimmer Biomet will post 7.8 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be paid a $0.24 dividend. The ex-dividend date is Wednesday, March 28th. This represents a $0.96 dividend on an annualized basis and a yield of 0.87%. Zimmer Biomet’s dividend payout ratio is currently 11.96%.
In related news, VP Chad F. Phipps sold 20,826 shares of Zimmer Biomet stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $115.95, for a total value of $2,414,774.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Bryan C. Hanson purchased 25,077 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The stock was purchased at an average price of $119.68 per share, with a total value of $3,001,215.36. The disclosure for this purchase can be found here. 0.71% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Zimmer Biomet (ZBH) Stock Price” was first posted by Week Herald and is the sole property of of Week Herald. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://weekherald.com/2018/04/21/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-zimmer-biomet-zbh-stock-price.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.